Literature DB >> 27978771

The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.

Kathleen M Carroll1, Roger D Weiss1.   

Abstract

OBJECTIVE: Although counseling is a required part of office-based buprenorphine treatment of opioid use disorders, the nature of what constitutes appropriate counseling is unclear and controversial. The authors review the literature on the role, nature, and intensity of behavioral interventions in office-based buprenorphine treatment.
METHOD: The authors conducted a review of randomized controlled studies testing the efficacy of adding a behavioral intervention to buprenorphine maintenance treatment.
RESULTS: Four key studies showed no benefit from adding a behavioral intervention to buprenorphine plus medical management, and four studies indicated some benefit for specific behavioral interventions, primarily contingency management. The authors examined the findings from the negative trials in the context of six questions: 1) Is buprenorphine that effective? 2) Is medical management that effective? 3) Are behavioral interventions that ineffective in this population? 4) How has research design affected the results of studies of buprenorphine plus behavioral treatment? 5) What do we know about subgroups of patients who do and those who do not seem to benefit from behavioral interventions? 6) What should clinicians aim for in terms of treatment outcome in buprenorphine maintenance?
CONCLUSIONS: High-quality medical management may suffice for some patients, but there are few data regarding the types of individuals for whom medical management is sufficient. Physicians should consider a stepped-care model in which patients may begin with relatively nonintensive treatment, with increased intensity for patients who struggle early in treatment. Finally, with 6-month retention rates seldom exceeding 50% and poor outcomes following dropout, we must explore innovative strategies for enhancing retention in buprenorphine treatment.

Entities:  

Keywords:  Addiction; Behavioral Treatment; Buprenorphine; Opioid Use Disorder; Psychotherapy; Treatment

Mesh:

Substances:

Year:  2016        PMID: 27978771      PMCID: PMC5474206          DOI: 10.1176/appi.ajp.2016.16070792

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  66 in total

Review 1.  Clinical trials in psychiatry: should protocol deviation censor patient data?

Authors:  P W Lavori
Journal:  Neuropsychopharmacology       Date:  1992-01       Impact factor: 7.853

2.  Buprenorphine therapy for opioid addiction in rural Washington: the experience of the early adopters.

Authors:  Tyler L Quest; Joseph O Merrill; John Roll; Andrew J Saxon; Roger A Rosenblatt
Journal:  J Opioid Manag       Date:  2012 Jan-Feb

3.  Contingent reinforcement increases cocaine abstinence during outpatient treatment and 1 year of follow-up.

Authors:  S T Higgins; C J Wong; G J Badger; D E Ogden; R L Dantona
Journal:  J Consult Clin Psychol       Date:  2000-02

4.  Feasibility of Implementing Shared Medical Appointments (SMAs) for Office-Based Opioid Treatment With Buprenorphine: A Pilot Study.

Authors:  Joji Suzuki; Jennifer Zinser; Brenda Klaiber; Melanie Hannon; Hope Grassi; Madeline Spinosa; Altagracia Ramirez; Mohammed Issa; Siu Ping Chin Feman
Journal:  Subst Abus       Date:  2015       Impact factor: 3.716

5.  Behavioral contingencies improve counseling attendance in an adaptive treatment model.

Authors:  Robert K Brooner; Michael S Kidorf; Van L King; Kenneth B Stoller; Jessica M Peirce; George E Bigelow; Ken Kolodner
Journal:  J Subst Abuse Treat       Date:  2004-10

6.  A randomized controlled trial of interim methadone maintenance.

Authors:  Robert P Schwartz; David A Highfield; Jerome H Jaffe; Joseph V Brady; Carol B Butler; Charles O Rouse; Jason M Callaman; Kevin E O'Grady; Robert J Battjes
Journal:  Arch Gen Psychiatry       Date:  2006-01

7.  Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence.

Authors:  Darren R Christensen; Reid D Landes; Lisa Jackson; Lisa A Marsch; Michael J Mancino; Mohit P Chopra; Warren K Bickel
Journal:  J Consult Clin Psychol       Date:  2014-08-04

8.  Computerized behavior therapy for opioid-dependent outpatients: a randomized controlled trial.

Authors:  Warren K Bickel; Lisa A Marsch; August R Buchhalter; Gary J Badger
Journal:  Exp Clin Psychopharmacol       Date:  2008-04       Impact factor: 3.157

9.  A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.

Authors:  Michael I Fingerhood; Van L King; Robert K Brooner; Darius A Rastegar
Journal:  Subst Abus       Date:  2014       Impact factor: 3.716

10.  A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification.

Authors:  Valerie A Gruber; Kevin L Delucchi; Anousheh Kielstein; Steven L Batki
Journal:  Drug Alcohol Depend       Date:  2008-04-01       Impact factor: 4.492

View more
  72 in total

1.  Medication-Assisted Treatment Use Among Pregnant Women With Opioid Use Disorder.

Authors:  Elizabeth E Krans; Joo Yeon Kim; Alton Everette James; David Kelley; Marian P Jarlenski
Journal:  Obstet Gynecol       Date:  2019-05       Impact factor: 7.661

2.  An evaluation of the feasibility, acceptability, and preliminary efficacy of cognitive-behavioral therapy for opioid use disorder and chronic pain.

Authors:  Declan T Barry; Mark Beitel; Christopher J Cutter; David A Fiellin; Robert D Kerns; Brent A Moore; Lindsay Oberleitner; Lynn M Madden; Christopher Liong; Joel Ginn; Richard S Schottenfeld
Journal:  Drug Alcohol Depend       Date:  2018-11-13       Impact factor: 4.492

Review 3.  Alcohol and Opioid Use, Co-Use, and Chronic Pain in the Context of the Opioid Epidemic: A Critical Review.

Authors:  Katie Witkiewitz; Kevin E Vowles
Journal:  Alcohol Clin Exp Res       Date:  2018-02-06       Impact factor: 3.455

4.  Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.

Authors:  Noa Krawczyk; Megan Buresh; Michael S Gordon; Thomas R Blue; Michael I Fingerhood; Deborah Agus
Journal:  J Subst Abuse Treat       Date:  2019-05-09

5.  Outpatient care for opioid use disorder among the commercially insured: Use of medication and psychosocial treatment.

Authors:  Alisa B Busch; Shelly F Greenfield; Sharon Reif; Sharon-Lise T Normand; Haiden A Huskamp
Journal:  J Subst Abuse Treat       Date:  2020-05-22

6.  Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone.

Authors:  Lesia M Ruglass; Jennifer Scodes; Martina Pavlicova; Aimee N C Campbell; Skye Fitzpatrick; Celestina Barbosa-Leiker; Kathleen Burlew; Shelly F Greenfield; John Rotrosen; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2019-10-21       Impact factor: 4.492

7.  Correlates of Opioid Abstinence in a 42-Month Posttreatment Naturalistic Follow-Up Study of Prescription Opioid Dependence.

Authors:  Roger D Weiss; Margaret L Griffin; David E Marcovitz; Blake T Hilton; Garrett M Fitzmaurice; R Kathryn McHugh; Kathleen M Carroll
Journal:  J Clin Psychiatry       Date:  2019-03-26       Impact factor: 4.384

8.  Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.

Authors:  Hillary Samples; Arthur Robin Williams; Mark Olfson; Stephen Crystal
Journal:  J Subst Abuse Treat       Date:  2018-09-07

Review 9.  Comparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: a Narrative Review.

Authors:  Simeon Kimmel; Paxton Bach; Alexander Y Walley
Journal:  J Gen Intern Med       Date:  2020-05-27       Impact factor: 5.128

10.  Primary Care Providers And Specialists Deliver Comparable Buprenorphine Treatment Quality.

Authors:  Alex K Gertner; Allison G Robertson; Byron J Powell; Hendree Jones; Pam Silberman; Marisa Elena Domino
Journal:  Health Aff (Millwood)       Date:  2020-08       Impact factor: 6.301

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.